Results 111 to 120 of about 47,580 (341)

Immunoglobulin G; structure and functional implications of different subclass modifications in initiation and resolution of allergy. [PDF]

open access: yes, 2017
IgE and not IgG is usually associated with allergy. IgE lodged on mast cells in skin or gut and basophils in the blood allows for the prolonged duration of allergy through the persistent expression of high affinity IgE receptors.
Amlot P. L.   +18 more
core   +2 more sources

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

open access: yesArthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Figure S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy [PDF]

open access: gold, 2023
Amr El Zawily   +23 more
openalex   +1 more source

Interleukin‐18 levels are associated with disease course in patients with Still's disease treated with IL‐1 inhibitors

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To evaluate the prognostic utility of circulating Interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in Still's disease (SD) patients receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan   +8 more
wiley   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis   +5 more
wiley   +1 more source

Correction: Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL [PDF]

open access: hybrid, 2023
Ze Tian   +19 more
openalex   +1 more source

[Bispecific antibodies: what future?].

open access: yesMedecine sciences : M/S, 2009
Monoclonal antibodies have emerged as a very successful class of therapeutic agents. In their native format, monoclonal antibodies are monospecific in that they recognize only one epitope, but their Fc domain also binds to FcfR-expressing cells. Attempts to improve the cytotoxicity of antibodies, particularly in the cancer field, have led to the design
Pèlegrin, André, Robert, Bruno
openaire   +2 more sources

An automated microfluidic biosensor with bispecific rabbit monoclonal antibody and nanozyme‐bioenzyme composite for dual antibiotic detection

open access: yesBMEMat, EarlyView.
This study introduces an automated microfluidic biosensor for simultaneous detection of florfenicol and thiamphenicol in environmental water. By integrating a phage‐screened bispecific rabbit monoclonal antibody with a nanozyme‐bioenzyme composite, the system achieves sensitive dual‐antibiotic detection. Coupled with smartphone‐based sensing, it offers
Fuyuan Zhang   +11 more
wiley   +1 more source

A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A. [PDF]

open access: yes, 2018
The standard of treatment for botulism, equine antitoxin, is a foreign protein with associated safety issues and a short serum half-life which excludes its use as a prophylactic antitoxin and makes it a less-than-optimal therapeutic.
Brown, Jennifer L   +14 more
core   +2 more sources

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

open access: green, 2022
Funda Meric‐Bernstam   +22 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy